Literature DB >> 19453755

Comparable studies of immunostimulating activities in vitro among Mycobacterium bovis bacillus Calmette-Guérin (BCG) substrains.

Daisuke Hayashi1, Takemasa Takii, Nagatoshi Fujiwara, Yukiko Fujita, Ikuya Yano, Saburo Yamamoto, Maki Kondo, Emi Yasuda, Emi Inagaki, Keita Kanai, Akiko Fujiwara, Aya Kawarazaki, Taku Chiba, Kikuo Onozaki.   

Abstract

During the serial passage of Mycobacterium bovis bacillus Calmette-Guérin (BCG) in different countries after initial seed distribution from the Pasteur Institute, specific insertions and deletions in the genome among BCG substrains were observed and speculated to result in differences in immunological activities. 'Early-shared strains' of BCG (Russia, Moreau, Japan, Sweden, Birkhaug), distributed by the Pasteur Institute, which conserve three types of mycolate (alpha, methoxy, keto) in cell wall, exhibited stronger activities of induction of nitric oxide, interleukin-1beta (IL-1beta), IL-6, IL-8, IL-12 and tumor necrosis factor (TNF)-alpha, from human epithelial cell line A549, human myelomonocytic cell line THP-1 and mouse bone marrow cells in the presence of interferon-gamma (IFN-gamma) than did 'late-shared strains' of BCG (Danish, Glaxo, Mexico, Tice, Connaught, Montreal, Phipps, Australia, Pasteur). The stronger induction of IL-12 and TNF-alpha in the presence of IFN-gamma was also observed by trehalose 6,6'-dimycolate (TDM) extracted from BCG-Japan than by TDM from BCG-Connaught, which lacks the methoxymycolate residue. These results suggest that 'early-shared strains' are more potent immunostimulating agents than 'late-shared strains', which could be attributed partially to methoxymycolate. Our study provides the basic information for immunological characterization of various BCG strains and may contribute to a re-evaluation of them as a reference strain for vaccination against tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19453755     DOI: 10.1111/j.1574-695X.2009.00559.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  18 in total

1.  Lipid phenotype of two distinct subpopulations of Mycobacterium bovis Bacillus Calmette-Guerin Tokyo 172 substrain.

Authors:  Takashi Naka; Shinji Maeda; Mamiko Niki; Naoya Ohara; Saburo Yamamoto; Ikuya Yano; Jun-Ichi Maeyama; Hisashi Ogura; Kazuo Kobayashi; Nagatoshi Fujiwara
Journal:  J Biol Chem       Date:  2011-10-26       Impact factor: 5.157

2.  Age-Specific Adjuvant Synergy: Dual TLR7/8 and Mincle Activation of Human Newborn Dendritic Cells Enables Th1 Polarization.

Authors:  Simon D van Haren; David J Dowling; Willemina Foppen; Dennis Christensen; Peter Andersen; Steven G Reed; Robert M Hershberg; Lindsey R Baden; Ofer Levy
Journal:  J Immunol       Date:  2016-10-28       Impact factor: 5.422

3.  Genome sequence of Mycobacterium bovis BCG Moreau, the Brazilian vaccine strain against tuberculosis.

Authors:  Leonardo H F Gomes; Thomas D Otto; Erico A Vasconcellos; Patrícia M Ferrão; Renata M Maia; Aline S Moreira; Marcelo A Ferreira; Luiz R R Castello-Branco; Wim M Degrave; Leila Mendonça-Lima
Journal:  J Bacteriol       Date:  2011-10       Impact factor: 3.490

Review 4.  Horizontal gene transfers with or without cell fusions in all categories of the living matter.

Authors:  Joseph G Sinkovics
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

Review 5.  Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy.

Authors:  Yuan-qiang Zheng; Youssef W Naguib; Yixuan Dong; Yan-chun Shi; Shorgan Bou; Zhengrong Cui
Journal:  Expert Rev Vaccines       Date:  2015       Impact factor: 5.217

6.  Intravesical Bacillus Calmette-Guerin (BCG) Therapy for Non-muscle Invasive Bladder Cancers: Long-term Results of a Modified Schedule.

Authors:  Kanuj Malik; Anand Raja; Lalgudi Subramaniam Ravishankar; Kathiresan Narayanaswamy; Venkatraman Radhakrishnan; Tenali Gnana Sagar
Journal:  Indian J Surg Oncol       Date:  2021-09-09

7.  Effectiveness of BCG vaccination to aged mice.

Authors:  Tsukasa Ito; Takemasa Takii; Mitsuo Maruyama; Daisuke Hayashi; Takeshi Wako; Azusa Asai; Yasuhiro Horita; Keiichi Taniguchi; Ikuya Yano; Saburo Yamamoto; Kikuo Onozaki
Journal:  Immun Ageing       Date:  2010-09-01       Impact factor: 6.400

8.  Genomic and proteomic analyses of Mycobacterium bovis BCG Mexico 1931 reveal a diverse immunogenic repertoire against tuberculosis infection.

Authors:  Patricia Orduña; Miguel A Cevallos; Samuel Ponce de León; Adriana Arvizu; Ismael L Hernández-González; Guillermo Mendoza-Hernández; Yolanda López-Vidal
Journal:  BMC Genomics       Date:  2011-10-08       Impact factor: 3.969

9.  Proteomic profile of culture filtrate from the Brazilian vaccine strain Mycobacterium bovis BCG Moreau compared to M. bovis BCG Pasteur.

Authors:  Marcia Berrêdo-Pinho; Dario E Kalume; Paloma R Correa; Leonardo H F Gomes; Melissa P Pereira; Renata F da Silva; Luiz R R Castello-Branco; Wim M Degrave; Leila Mendonça-Lima
Journal:  BMC Microbiol       Date:  2011-04-20       Impact factor: 3.605

10.  Severe osteomyelitis as a complication of Tokyo-172 BCG vaccination.

Authors:  Hyo Jin Kwon; Bo Hyun Chung; Byung Min Choi; Kyung Un Park; Yun Kyung Kim
Journal:  J Korean Med Sci       Date:  2012-01-27       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.